Making sense of SGLT-2 inhibitors in daily practice – 2026 Clinical update of CRM therapy
This practice-orientated review focuses on the safe and effective early use of SGLT-2 inhibitors across the continuum of T2DM
Learning objectives
You will learn:
- To understand the inter-relationship between the cardiorenal metabolic system and type 2 diabetes mellitus (T2DM)
- To practically apply guideline-led therapy in T2DM patients in defined clinical categories
- To initiate SGLT-2 inhibitors safely and effectively early in the continuum of T2DM.
To access this module, please register or login: